1
|
Leerling AT, Weizenbach CCJ, Navas-Cañete A, Dekkers OM, Winter EM. Evolution of bone lesions in adults with chronic nonbacterial osteitis (CNO): A long-term follow-up study. Semin Arthritis Rheum 2025; 71:152658. [PMID: 39970621 DOI: 10.1016/j.semarthrit.2025.152658] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2024] [Revised: 01/20/2025] [Accepted: 02/03/2025] [Indexed: 02/21/2025]
Abstract
OBJECTIVES Chronic nonbacterial osteitis (CNO) is a rare disease characterised by sterile bone inflammation. Little is known about the evolution of bone lesions, especially for the adult variant of the disease (adult CNO). We therefore aimed to characterize the radiologic course of adult CNO. METHODS We conducted a cohort study among confirmed adults with CNO, treated at the Dutch national CNO referral centre between 1992 and 2023. Imaging reports from the first-performed radiological scan (baseline) to the last available scan (end of follow-up) were systematically reviewed for lesion location and radiologic features (sclerosis, hyperostosis, erosions, ankylosis). Incidence rates (IRs) for new lesions, progression, and regression of existing lesions were estimated using the Poisson method. Kaplan-Meier curves were used to visualize cumulative incidence, and Poisson regression models assessed associations between patient characteristics and the outcomes. RESULTS The study included 182 adult CNO patients with a mean follow-up of 6.1 ± 5.2 years, treated with nonsteroidal anti-inflammatory drugs or cyclooxygenase-inhibitors and/or intravenous bisphosphonates or tumour necrosis factor alpha inhibitors. The most common pattern was sole involvement of the anterior chest wall (84 %). IRs per 100 person-years were 4 (95 % CI 3-5) (new lesions), 7 (6-9) (progression), and 1 (0.3.-1) (regression). Among patients with anterior chest wall involvement only (n = 147), one person developed a lesion outside this area (IR 0.3 (0.06-1)). At 2 years, cumulative incidence of new lesion development and progression were 2 % (0-5) and 7 % (3-10), increasing to 11 % (5-17) and 29 % (20-36) at 5 years, and 36 % (23-48) and 56 % (43-64) at 10 years. No associations were found between clinical characteristics at baseline and these outcomes. CONCLUSIONS The development of new bone lesions in treated adult CNO patients is typically confined to previously affected regions, primarily the anterior chest wall. Progression of structural changes occurs in the majority of patients after longer follow-up. These findings can be used for prognostic counselling, and suggest that routine whole-body imaging may not be necessary for most patients during follow-up.
Collapse
Affiliation(s)
- Anne T Leerling
- Department of Internal Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands; Center for Bone Quality, Leiden University Medical Center, Leiden, The Netherlands; Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
| | - Christophe C J Weizenbach
- Department of Internal Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands; Center for Bone Quality, Leiden University Medical Center, Leiden, The Netherlands; Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
| | - Ana Navas-Cañete
- Center for Bone Quality, Leiden University Medical Center, Leiden, The Netherlands; Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands
| | - O M Dekkers
- Department of Internal Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands; Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
| | - E M Winter
- Department of Internal Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands; Center for Bone Quality, Leiden University Medical Center, Leiden, The Netherlands.
| |
Collapse
|
2
|
Öksüz Aydın B, Aydın F, Taş Ö, Bahçeci O, Özçakar ZB. Associated diseases and their effects on disease course in patients with chronic non-bacterial osteomyelitis: retrospective experience from a single center. Clin Rheumatol 2025; 44:855-862. [PMID: 39808231 PMCID: PMC11774977 DOI: 10.1007/s10067-025-07306-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2024] [Revised: 12/20/2024] [Accepted: 12/30/2024] [Indexed: 01/16/2025]
Abstract
OBJECTIVE Chronic non-bacterial osteomyelitis (CNO) is a rare autoinflammatory bone disease associated with other chronic inflammatory diseases such as familial Mediterranean fever (FMF), juvenile idiopathic arthritis (JIA), spondylarthropathies, inflammatory bowel disease (IBD), and pyoderma gangrenosum. We aimed to describe the clinical and follow-up characteristics of patients with CNO and to compare findings between patients with and without comorbidities. METHODS The clinical records of patients with CNO who were followed up in our pediatric rheumatology clinic between 2018 and 2023 were reviewed. Patients were divided into two groups according to the presence or absence of comorbidities. The clinical, laboratory, and radiological characteristics and treatments of the groups were compared. RESULTS The study included 40 patients (65% male) diagnosed with CNO. The median (IQR) age at symptom onset was 10 (6.4) and at diagnosis was 11.5 (5.9) years. Fourteen (35%) patients had comorbidities. The comorbidities were FMF (n = 9), IBD (n = 3), uveitis (n = 3), psoriasis (n = 1) and acne conglabatae (n = 2). The group with comorbidities had higher number of bones involved (3 or more bones) (78.6% versus 42.3%) (p = 0.028), and 78.6% of patients with comorbidities received biologic treatment, while only 23.1% of patients without comorbidities were treated with biologics (p = 0.001). CONCLUSION Familial Mediterranean fever, uveitis, IBD, psoriasis and acne conglabata were found to be the clinical conditions associated with CNO. Patients with CNO who had comorbidities appeared to have a more severe phenotype of the disease accompanied with more bone involvement and requiring more biologic treatment. Key Points • Chronic non-bacterial osteomyelitis (CNO), an auto-inflammatory bone disease, can be seen in association with other inflammatory conditions such as familial Mediterranean fever (FMF), uveitis, inflammatory bowel disease (IBD), psoriasis, and acne conglobata. • If CNO is associated with another inflammatory disease, the number of bones involved may be higher and patients may need more intensive treatments, such as biologics. • CNO may coexist with one or more inflammatory diseases, which may exacerbate the disease phenotype.
Collapse
Affiliation(s)
- Betül Öksüz Aydın
- Division of Pediatric Rheumatology, Department of Pediatrics, Ankara University Faculty of Medicine, Ankara, Turkey
| | - Fatma Aydın
- Division of Pediatric Rheumatology, Department of Pediatrics, Ankara University Faculty of Medicine, Ankara, Turkey.
| | - Özen Taş
- Division of Pediatric Rheumatology, Department of Pediatrics, Ankara University Faculty of Medicine, Ankara, Turkey
| | - Onur Bahçeci
- Division of Pediatric Rheumatology, Department of Pediatrics, Ankara University Faculty of Medicine, Ankara, Turkey
| | - Zeynep Birsin Özçakar
- Division of Pediatric Rheumatology and Nephrology, Department of Pediatrics, Ankara University Faculty of Medicine, Ankara, Turkey
| |
Collapse
|
3
|
Kruger C, Wang C, Grim A. Paediatric SAPHO syndrome with pleural effusion: Case report of a unique finding in a rare disease. Mod Rheumatol Case Rep 2025; 9:168-173. [PMID: 39082151 DOI: 10.1093/mrcr/rxae038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2024] [Revised: 06/24/2024] [Accepted: 07/24/2024] [Indexed: 01/18/2025]
Abstract
Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome is a rare autoinflammatory disease characterised by bone inflammation and skin manifestations including acne, palmoplantar pustulosis, psoriasis, or hidradenitis suppurativa. SAPHO syndrome is considered on the same spectrum as chronic nonbacterial osteomyelitis/chronic recurrent multifocal osteomyelitis, the former often being the nomenclature in adults and the latter in children. The diagnosis is made on patterns of clinical manifestations and is a diagnosis of exclusion. While skin and bone manifestations are commonly described with SAPHO syndrome, pleural involvement is rare, and few cases have been described in the literature, especially in paediatric patients. Herein we present a 14-year-old female with a past medical history of hidradenitis supprtiva, eczema, psoriasis, and a prior episode of culture-negative osteomyelitis who presented to the emergency room with chief complaints of right-sided pain with inspiration and back pain. Exam revealed palmoplantar pustulosis, hidradenitis supprativa, psoriasis, and tenderness of vertebrae. Imaging showed a right-sided pleural effusion and multiple sites of osteitis. Laboratory evaluation revealed elevated inflammatory markers, an exudative pleural effusion with neutrophilic predominance, and no evidence of malignancy, infection, or immunodeficiency. The patient was diagnosed with SAPHO syndrome and treated with naproxen, methotrexate, and golimumab with significant improvement including resolution of the pleural effusion. Paediatric SAPHO syndrome is a rare disease that classically causes osteitis and skin manifestations. This case highlights that pleural effusion can be a rare manifestation of paediatric SAPHO syndrome. Patients with suspected SAPHO syndrome with respiratory symptoms should be evaluated for pleural effusion.
Collapse
Affiliation(s)
- Christopher Kruger
- Division of General Pediatrics, University of Michigan C. S. Mott Children's Hospital, Ann Arbor, MI, 48109 United States
| | - Christine Wang
- Division of Pediatric Rheumatology, University of Michigan C. S. Mott Children's Hospital, Ann Arbor, MI, 48109 United States
| | - Andrew Grim
- Division of Pediatric Rheumatology, University of Michigan C. S. Mott Children's Hospital, Ann Arbor, MI, 48109 United States
| |
Collapse
|
4
|
Borges T, Santos J, Silva S. Sterile osteomyelitis: a cardinal sign of autoinflammation. Reumatologia 2024; 62:475-488. [PMID: 39866303 PMCID: PMC11758105 DOI: 10.5114/reum/196595] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2024] [Accepted: 11/28/2024] [Indexed: 01/28/2025] Open
Abstract
Autoinflammatory bone disorders (ABDs) are characterized by sterile bone inflammation stemming from dysregulated innate immune responses. This review focuses on the occurrence of sterile osteomyelitis in ABDs and related diseases, notably chronic nonbacterial osteomyelitis (CNO) and its sporadic and monogenic forms, such as deficiency of the interleukin-1 (IL-1) receptor antagonist, Majeed syndrome, CNO related to FBLIM1 mutation, and pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA syndrome). Additionally, other autoinflammatory disorders (AIDs) are discussed, including classical periodic fever syndromes (e.g., familial Mediterranean fever, cryopyrin-associated periodic syndromes), monogenic rare AIDs (such as hyperostosis-hyperphosphatemia syndrome, H syndrome, interferonopathies, and Singleton-Merten's syndrome), polygenic AIDs with bone involvement (e.g., Schnitzler's syndrome, systemic juvenile idiopathic arthritis, adult-onset Still's disease, and calcium pyrophosphate deposition disease), and bone dysplastic syndromes. Sterile osteomyelitis emerges as a cardinal sign of autoinflammation, aiding clinicians in both diagnosis and management of ABDs. Treatment typically involves tumor necrosis factor inhibitors or IL-1 antagonists.
Collapse
Affiliation(s)
- Tiago Borges
- Department of Internal Medicine, Trofa Saúde Hospital Privado em Gaia, Vila Nova de Gaia, Portugal
| | | | - Sérgio Silva
- Department of Internal Medicine, Trofa Saúde Hospital Privado em Gaia, Vila Nova de Gaia, Portugal
| |
Collapse
|
5
|
Ożga J, Mężyk E, Kmiecik W, Wojciechowski W, Żuber Z. Coexisting Sacroiliac Arthritis and Chronic Nonbacterial Osteomyelitis in an Adolescent with Ehlers-Danlos Syndrome: A Case Report and Treatment Success. AMERICAN JOURNAL OF CASE REPORTS 2024; 25:e943579. [PMID: 39306669 PMCID: PMC11426177 DOI: 10.12659/ajcr.943579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/28/2024]
Abstract
BACKGROUND Chronic nonbacterial osteomyelitis (CNO) is a multifocal autoinflammatory bone disease mainly affecting children and adolescents. Sacroiliitis is an inflammation of the sacroiliac joint, diagnosed with the use of musculoskeletal MRI due to its ability to visualize active inflammatory lesions. Ehlers-Danlos syndrome (EDS) is non-inflammatory hereditary disorder of connective tissue. Here, we report the case of a 17.5-year-old female patient with classical EDS and long-term course of the CNO with coexistence of sacroiliac arthritis. CASE REPORT On admission, a patient with CNO reported pain in the scapula, thoracic spine, shoulders, and iliac region, with morning stiffness present for 5 months. Physical examination revealed knee and elbow joint hyperextension, hypermobility of the phalanges, increased range of motion of the hip joints, and the presence of reticular rash on the face. In the laboratory blood tests, minor leukocytosis was reported. During hospitalization, a whole-body MRI was performed, detecting bone marrow edema in the Th3, Th4, and Th7 vertebral bodies and the head of seventh rib on the left side, as well as bilaterally in the sacroiliac joints. The patient was diagnosed with sacroiliitis and EDS and successfully treated with risedronate sodium, methotrexate with folic acid, sulfasalazine, and meloxicam, achieving CNO remission and reduced severity of axial skeleton pain. CONCLUSIONS The coexistence of these 3 diseases - CNO, sacroiliac arthritis, and EDS - in the same patient is rare and requires interphysician collaboration to determine the correct diagnosis and subsequently arrange multi-speciality therapeutic management to achieve remission.
Collapse
Affiliation(s)
- Joanna Ożga
- Department of Pediatrics, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Cracow University, Cracow, Poland
- Clinical Department of Pediatrics and Rheumatology, St. Louis Regional Specialised Children's Hospital, Cracow, Poland
| | - Elżbieta Mężyk
- Department of Pediatrics, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Cracow University, Cracow, Poland
- Clinical Department of Pediatrics and Rheumatology, St. Louis Regional Specialised Children's Hospital, Cracow, Poland
| | - Wojciech Kmiecik
- Department of Pediatrics, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Cracow University, Cracow, Poland
- Clinical Department of Pediatrics and Rheumatology, St. Louis Regional Specialised Children's Hospital, Cracow, Poland
| | - Wadim Wojciechowski
- Clinical Department of Pediatrics and Rheumatology, St. Louis Regional Specialised Children's Hospital, Cracow, Poland
- Department of Radiology, Jagiellonian University Medical College, Cracow, Poland
| | - Zbigniew Żuber
- Department of Pediatrics, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Cracow University, Cracow, Poland
- Clinical Department of Pediatrics and Rheumatology, St. Louis Regional Specialised Children's Hospital, Cracow, Poland
| |
Collapse
|
6
|
Robert M, Giolito A, Reumaux H, Rossi-Semerano L, Guillemin C, Biarrotte L, Leguevaques D, Belot A, Duquesne A, Frachette C, Laurent A, Desjonquères M, Larbre JP, Galeotti C, Koné-Paut I, Dusser P. Extra-osseous manifestations in chronic recurrent multifocal osteomyelitis: a retrospective study. Rheumatology (Oxford) 2024; 63:SI233-SI239. [PMID: 37698983 DOI: 10.1093/rheumatology/kead473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2023] [Revised: 08/10/2023] [Accepted: 08/23/2023] [Indexed: 09/14/2023] Open
Abstract
OBJECTIVES Extra-osseous (EO) manifestations are poorly characterized in chronic recurrent multifocal osteomyelitis (CRMO). This study aimed to further define the frequency, characteristics and treatment of EO events in CRMO and whether different phenotypes can be distinguished and benefit from special management. METHODS This multicentre retrospective study included CRMO patients followed in several paediatric rheumatology departments in France between 2015 and 2022. EO manifestations were defined as skin lesions, gastrointestinal manifestations, arthritis, enthesitis, sacroiliitis, uveitis, vasculitis and fever. At the last visit, the physician defined CRMO as active in the presence of clinical manifestations including both osseous and EO symptoms. RESULTS We included 133 patients; 87 (65.4%) were girls and the median age at first symptoms was 9.0 years (interquartile range 7.0-10.0). EO manifestations were described in 90 (67.7%) patients, with a predominance of skin lesions [n = 51/90 (56.7%)], followed by sacroiliitis [n = 38/90 (42.2%)], enthesitis [n = 21/90 (23.3%)], arthritis [n = 14/90 (15.6%)] and gastrointestinal manifestations [n = 6/90 (6.7%)]. The use of non-steroidal anti-inflammatory drugs and bisphosphonates did not differ by the presence or not of EO manifestations. Biologics were taken more frequently by patients with than without EO manifestations (P < 0.001); TNF inhibitors were used in 33 (36.7%) EO-positive patients. Under this treatment, 18 (54.5%) patients achieved complete remission of osseous and EO manifestations. At the last visit, more EO+ than EO- patients were on treatment (P = 0.009), with active disease in 58 (64.4%) patients. CONCLUSION The analysis of EO manifestations in CRMO delineates two groups of patients in terms of severity and treatments used. Our study opens up new pathophysiological leads that may underlie the wide range of CRMO phenotypes.
Collapse
Affiliation(s)
- Marie Robert
- Service de Rhumatologie Pédiatrique, Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses Inflammatoires (CEREMAIA), Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin-Bicêtre, France
- Université Paris-Cité, Paris, France
| | - Anna Giolito
- Service de Rhumatologie Pédiatrique, Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses Inflammatoires (CEREMAIA), Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin-Bicêtre, France
- Université Paris-Cité, Paris, France
| | - Heloise Reumaux
- Service de Rhumatologie Pédiatrique, Centre Hospitalier Universitaire de Lille, Lille, France
| | - Linda Rossi-Semerano
- Service de Rhumatologie Pédiatrique, Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses Inflammatoires (CEREMAIA), Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin-Bicêtre, France
- Réseau Rhumatismes Inflammatoires Pédiatriques (RESRIP), Bourg-La-Reine, France
| | - Claire Guillemin
- Service de Rhumatologie Pédiatrique, Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses Inflammatoires (CEREMAIA), Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin-Bicêtre, France
- Université Paris-Cité, Paris, France
| | - Louis Biarrotte
- Service de Rhumatologie Pédiatrique, Centre Hospitalier Universitaire de Lille, Lille, France
| | - Damia Leguevaques
- Service de Rhumatologie Pédiatrique, Centre Hospitalier Universitaire de Lille, Lille, France
| | - Alexandre Belot
- Service de Néphrologie-Rhumatologie-Dermatologie Pédiatriques, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France
- Centre de Référence des Rhumatismes Inflammatoires et Maladies Auto-Immunes Rares de l'Enfant (RAISE), France
| | - Agnès Duquesne
- Service de Néphrologie-Rhumatologie-Dermatologie Pédiatriques, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France
- Centre de Référence des Rhumatismes Inflammatoires et Maladies Auto-Immunes Rares de l'Enfant (RAISE), France
| | - Cécile Frachette
- Service de Néphrologie-Rhumatologie-Dermatologie Pédiatriques, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France
- Centre de Référence des Rhumatismes Inflammatoires et Maladies Auto-Immunes Rares de l'Enfant (RAISE), France
| | - Audrey Laurent
- Service de Néphrologie-Rhumatologie-Dermatologie Pédiatriques, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France
- Centre de Référence des Rhumatismes Inflammatoires et Maladies Auto-Immunes Rares de l'Enfant (RAISE), France
| | - Marine Desjonquères
- Service de Néphrologie-Rhumatologie-Dermatologie Pédiatriques, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France
- Centre de Référence des Rhumatismes Inflammatoires et Maladies Auto-Immunes Rares de l'Enfant (RAISE), France
| | - Jean-Paul Larbre
- Service de Rhumatologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France
| | - Caroline Galeotti
- Service de Rhumatologie Pédiatrique, Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses Inflammatoires (CEREMAIA), Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin-Bicêtre, France
| | - Isabelle Koné-Paut
- Service de Rhumatologie Pédiatrique, Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses Inflammatoires (CEREMAIA), Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin-Bicêtre, France
- Université Paris-Saclay, Paris, France
| | - Perrine Dusser
- Service de Rhumatologie Pédiatrique, Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses Inflammatoires (CEREMAIA), Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin-Bicêtre, France
- Réseau Rhumatismes Inflammatoires Pédiatriques (RESRIP), Bourg-La-Reine, France
- Université Paris-Saclay, Paris, France
| |
Collapse
|
7
|
Bouchalova K, Pytelova Z. Chronic non-bacterial osteomyelitis (CNO) and chronic recurrent multifocal osteomyelitis (CRMO) with a focus on pamidronate therapy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2024; 168:191-199. [PMID: 38682664 DOI: 10.5507/bp.2024.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2024] [Accepted: 02/28/2024] [Indexed: 05/01/2024] Open
Abstract
Chronic recurrent multifocal osteomyelitis (CRMO), also called chronic nonbacterial osteomyelitis (CNO) or nonbacterial osteomyelitis (NBO), is a rare autoinflammatory bone disease of unknown etiology. However, the number of patients properly diagnosed would increase with better knowledge of the disease. In this regard, whole-body magnetic resonance imaging (WB MRI) has been found to be a better predictor of active lesions than clinical examination. Importantly, the RINBO index (radiologic index for NBO) quantifies the involvement based on the WB MRI. Further, a chronic nonbacterial osteomyelitis MRI scoring (CROMRIS) has been developed as an online tool for assessing WB MRI. The therapy consists of non-steroidal anti-inflammatory drugs (NSAIDs), bisphosphonates (pamidronate, zoledronate, etc.) and other drugs, including biologics. Pamidronate is an appropriate and safe therapy. The first pilot prospective randomised controlled trial (RCT) on pamidronate vs. placebo was carried out in adults. No RCT has been done in children yet. Besides RCTs, there are a number of issues to be explored in future, i.e. predictors of therapy effect, optimal therapy duration, predictors of therapy discontinuation and evaluation of optimal therapy protocol. Recently, the CNO clinical disease activity score (CDAS) was constructed and validated but the classification criteria are still being developed. As collaboration on this rare disease is essential, a prospective Chronic Nonbacterial Osteomyelitis International Registry (CHOIR) was established to generate future comparative effectiveness research data.
Collapse
Affiliation(s)
- Katerina Bouchalova
- Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic
| | - Zuzana Pytelova
- Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic
| |
Collapse
|
8
|
Lanckoroński M, Gietka P, Mańczak M, Sudoł-Szopińska I. Whole-Body MRI at Initial Presentation of Chronic Recurrent Multifocal Osteomyelitis, Juvenile Idiopathic Arthritis, Their Overlapping Syndrome, and Non-Specific Arthropathy. J Clin Med 2024; 13:998. [PMID: 38398312 PMCID: PMC10888598 DOI: 10.3390/jcm13040998] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2024] [Revised: 02/02/2024] [Accepted: 02/07/2024] [Indexed: 02/25/2024] Open
Abstract
(1) Background: Whole-body magnetic resonance imaging (WB-MRI) is central to defining total inflammatory burden in juveniles with arthritis. Our aim was to determine and compare the initial distribution of lesions in the WB-MRI in patients with chronic recurrent multifocal osteomyelitis (CRMO), juvenile idiopathic arthritis (JIA), their overlapping syndrome (OS), and with Non-specific Arthropathy (NA). (2) Methods: This retrospective single center study was performed on an Avanto 1.5-T MRI scanner with a dedicated multichannel surface coil system. A total of 173 pediatric patients were included with the following final diagnoses: CRMO (15.0%), JIA (29.5%), OS (4.6%), and NA (50.9%). (3) Results: Bone marrow edema (BME) was the most common abnormality, being seen in 100% patients with CRMO, 88% with OS, 55% with JIA, and 11% with NA. The bones of the lower extremities were the most affected in all compared entities. Effusion was seen in 62.5% children with OS, and in 52.9% with JIA, and in CRMO and NA, the exudate was sporadic. Enthesitis was found in 7.8% of patients with JIA and 3.8% with CRMO, and myositis was seen in 12.5% of patients with OS and in 3.9% with JIA. (4) Conclusions: The most frequent indication for WB-MRI in our center was JIA. The most common pathology in all rheumatic entities was BME, followed by effusion mainly seen in in OS and JIA. Enthesitis and myositis were less common; no case was observed in NA.
Collapse
Affiliation(s)
- Michał Lanckoroński
- Department of Radiology, National Institute of Geriatrics, Rheumatology and Rehabilitation, 1 Spartańska Street, 02-637 Warsaw, Poland
| | - Piotr Gietka
- Clinic of Paediatric Rheumatology, National Institute of Geriatrics, Rheumatology and Rehabilitation, 1 Spartańska Street, 02-637 Warsaw, Poland;
| | - Małgorzata Mańczak
- Department of Gerontology, Public Health and Didactics, National Institute of Geriatrics, Rheumatology and Rehabilitation in Warsaw, 1 Spartańska Street, 02-637 Warsaw, Poland;
| | - Iwona Sudoł-Szopińska
- Department of Radiology, National Institute of Geriatrics, Rheumatology and Rehabilitation, 1 Spartańska Street, 02-637 Warsaw, Poland
| |
Collapse
|
9
|
Abstract
Chronic recurrent multifocal osteomyelitis (CRMO) is an underrecognized autoinflammatory disease affecting the skeletal system. Its vague symptoms are often first attributed to growing pains, infection, or malignancy, which can lead to a delay in diagnosis for days to years. Untreated CRMO has the potential to cause debilitating skeletal deformities, arthritis, and chronic pain; hence early recognition and treatment are paramount. MRI is the gold standard for diagnosis. Treatment consists of various antiinflammatory medications and may also include bisphosphonates if vulnerable skeletal sites are involved. Even when treated, the disease may have a relapsing course lasting years.
Collapse
Affiliation(s)
- Bridget A Rafferty
- Medical College of Wisconsin, 8701 W. Watertown Plank Road, Milwaukee, WI 53226, USA
| | - Pooja Thakrar
- Medical College of Wisconsin/Children's Wisconsin, 9000 W. Wisconsin Avenue, MS-721, Milwaukee, WI 53226, USA.
| |
Collapse
|